BASELINE GENOTYPE AND HBSAG WERE FOUND TO HAVE SIGNIFICANT ASSOCIATION WITH HBEAG SEROCONVERSION FOLLOWING UP TO 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE TREATMENT

POSTERSHBsAg decline >0.5 log 10 at week 12 (40% vs 4%, p = 0.03) or >1 log 10 at week 24 (40% vs 0%, p = 0.004).Conclusions: In HBeAg-negative CHB patients, a significant mean decline in HBsAg levels from baseline was first observed at 24 weeks of treatment with peginterferon-alfa-2a.Early HBsAg decline is associated with on-treatment virological response, while its potential associations with post-treatment responses remain to be evaluated.